Zacks Research Issues Pessimistic Estimate for EHC Earnings

Encompass Health Co. (NYSE:EHC) – Research analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for Encompass Health in a research report issued on Wednesday, January 8th. Zacks Research analyst Z. Masood now forecasts that the company will post earnings per share of $1.23 for the quarter, down from their previous forecast of $1.25. The consensus estimate for Encompass Health’s current full-year earnings is $4.29 per share. Zacks Research also issued estimates for Encompass Health’s Q2 2025 earnings at $1.21 EPS, FY2025 earnings at $4.73 EPS, Q1 2026 earnings at $1.33 EPS, Q3 2026 earnings at $1.23 EPS, Q4 2026 earnings at $1.30 EPS and FY2026 earnings at $5.27 EPS.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Monday, October 28th. The company reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.09. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company earned $0.86 EPS.

Several other equities analysts have also recently issued reports on the stock. Barclays boosted their price target on shares of Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research report on Tuesday, October 29th. UBS Group increased their target price on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Royal Bank of Canada lifted their price target on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Truist Financial reiterated a “buy” rating and issued a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Finally, KeyCorp boosted their target price on shares of Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a report on Tuesday, October 29th. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $107.11.

Encompass Health Stock Up 0.4 %

Shares of Encompass Health stock opened at $92.95 on Monday. The company’s fifty day simple moving average is $97.91 and its two-hundred day simple moving average is $93.88. Encompass Health has a 12-month low of $67.94 and a 12-month high of $104.55. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.88. The company has a market cap of $9.36 billion, a P/E ratio of 22.45, a PEG ratio of 1.30 and a beta of 0.89.

Institutional Investors Weigh In On Encompass Health

Several institutional investors and hedge funds have recently made changes to their positions in EHC. UMB Bank n.a. boosted its stake in Encompass Health by 387.7% during the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock valued at $31,000 after purchasing an additional 252 shares during the last quarter. V Square Quantitative Management LLC boosted its position in shares of Encompass Health by 53.0% during the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after buying an additional 140 shares during the last quarter. Avior Wealth Management LLC bought a new stake in Encompass Health in the 3rd quarter worth about $40,000. Benjamin F. Edwards & Company Inc. raised its position in Encompass Health by 58.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock worth $46,000 after buying an additional 198 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Encompass Health during the 2nd quarter valued at about $58,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.73%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health’s dividend payout ratio (DPR) is 16.43%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.